IQVIA Biotech was selected to help a U.S. biopharmaceutical company examine the safety and efficacy of its investigational therapy for the treatment of moderate-to-severe hidradenitis suppurativa (HS).

This case study will highlight IQVIA Biotech's unique strategies for site selection and centralized recruitment. Aiming to reach enrollment targets within 66 weeks, by leveraging IQVIA CORE data and therapeutic expertise, the team met initial enrollment targets two weeks early – in the midst of the COVID-19 pandemic.